KALV
Kalvista Pharmaceuticals Inc
NASDAQ: KALV · HEALTHCARE · BIOTECHNOLOGY
$26.66
+0.04% today
Updated 2026-05-04
Market cap
$1.42B
P/E ratio
—
P/S ratio
19.29x
EPS (TTM)
$-3.94
Dividend yield
—
52W range
$10 – $27
Volume
2.9M
Kalvista Pharmaceuticals Inc (KALV) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.54M | $415000.00 | $29000.00 | $1.80M | $29000.00 | $7000.00 | $2.13M | $1.50M | $8.39M | $16.13M | $12.69M | $12.69M | $0.00 | $0.00 | $0.00 | $0.00 | $73.62M |
| Revenue growth (YoY) | — | -73.0% | -93.0% | +6120.7% | -98.4% | -75.9% | +30371.4% | -29.5% | +458.1% | +92.1% | -21.3% | +0.0% | -100.0% | — | — | — | — |
| Cost of revenue | — | — | — | $8285.00 | $0.00 | $0.00 | $14661.00 | $12666.00 | $18237.00 | $35021.00 | $40.19M | $41.29M | $743000.00 | $802000.00 | $86.17M | $941000.00 | $6.08M |
| Gross profit | $1.54M | $415000.00 | — | $1.80M | $29000.00 | $7000.00 | $2.12M | $1.49M | $8.38M | $16.09M | $-27.50M | $-41.29M | $-743000.00 | $-802000.00 | $-86.17M | $-941000.00 | $67.54M |
| Gross margin | 100.0% | 100.0% | 0.0% | 99.5% | 100.0% | 100.0% | 99.3% | 99.2% | 99.8% | 99.8% | -216.7% | -325.3% | — | — | — | — | 91.7% |
| R&D | $1.96M | $4.23M | — | $8.29M | $16.20M | $3.53M | $14.66M | $12.67M | $18.24M | $35.02M | $40.19M | $41.29M | $70.17M | $80.28M | $86.17M | $71.71M | $55.64M |
| SG&A | $1.41M | $1.40M | $3.41M | $1.61M | $4.87M | $1.54M | $2.65M | $11.18M | $8.86M | $10.93M | $13.03M | $16.64M | $26.45M | $30.59M | $54.28M | $116.29M | — |
| Operating income | $-1.83M | $-5.22M | $-11.68M | $-8.09M | $-24.21M | $-6.53M | $-15.18M | $-22.34M | $-18.70M | $-29.82M | $-40.53M | $-57.92M | $-96.61M | $-110.87M | $-140.44M | $-188.00M | $-171.84M |
| Operating margin | -119.2% | -1256.9% | -40265.5% | -448.4% | -83493.1% | -93257.1% | -711.7% | -1485.3% | -222.8% | -184.9% | -319.4% | -456.4% | — | — | — | — | -233.4% |
| EBITDA | $-1.76M | $-5.25M | — | $-8.05M | — | — | $-15.15M | $-22.30M | $-18.52M | $-29.44M | $-40.02M | $-57.39M | $-80.75M | $-94.37M | $-134.28M | $-173.33M | $-170.38M |
| EBITDA margin | -114.4% | -1264.1% | 0.0% | -446.3% | 0.0% | 0.0% | -710.2% | -1482.6% | -220.7% | -182.6% | -315.4% | -452.2% | — | — | — | — | -231.4% |
| EBIT | $-1.80M | $-5.27M | — | $-8.09M | $-23.66M | $-6.52M | $-15.28M | $-22.34M | $-18.70M | $-29.82M | $-40.53M | $-57.92M | $-81.31M | $-95.09M | $-135.10M | $-174.27M | $-171.84M |
| Interest expense | $256000.00 | $405000.00 | $0.00 | $863000.00 | $0.00 | $0.00 | $3.75M | $3.74M | $2.90M | $9.18M | $10.93M | $903000.00 | $1.09M | $17.96M | $0.00 | $5.79M | $19.34M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.05M | $-5.68M | $-13.36M | $-7.23M | $-24.85M | $-6.61M | $-11.44M | $-18.60M | $-15.80M | $-20.82M | $-29.12M | $-46.24M | $-82.34M | $-92.91M | $-126.64M | $-183.44M | $-164.29M |
| Net income growth (YoY) | — | -176.6% | -135.3% | +45.9% | -243.8% | +73.4% | -73.1% | -62.7% | +15.0% | -31.7% | -39.9% | -58.8% | -78.1% | -12.8% | -36.3% | -44.9% | +10.4% |
| Profit margin | -133.5% | -1368.2% | -46065.5% | -400.6% | -85675.9% | -94385.7% | -536.1% | -1236.9% | -188.3% | -129.1% | -229.4% | -364.4% | — | — | — | — | -223.2% |